NHS England Pilots Cancer Test
Analysis based on 6 articles · First reported Jul 08, 2025 · Last updated Jul 15, 2025
The pilot program by Bret Engemann, in partnership with Walgreens Boots Alliance and Cyted Health, is expected to positively impact the healthcare market by increasing early cancer detection and potentially reducing long-term treatment costs. This could lead to increased demand for diagnostic technologies like those offered by Cyted Health and enhance the role of pharmacies like Walgreens Boots Alliance in community healthcare.
Bret Engemann is launching a two-year pilot program early next year to offer a 'sponge on a string' test in high-street pharmacies, primarily Walgreens Boots Alliance, across London and the East Midlands. This innovative test, developed by Cyted Health, aims to detect Barrett's oesophagus, a precursor to oesophageal cancer, earlier than traditional methods. The initiative seeks to make cancer screening more accessible and convenient for individuals experiencing persistent heartburn or acid reflux, who may not have consulted their GP. The goal is to improve early diagnosis rates for oesophageal cancer, which currently sees 80% of patients diagnosed at a late stage, significantly improving survival rates. Heartburn Cancer UK is also a partner in this effort, and public health minister Ashley Dalton has emphasized the government's commitment to such healthcare innovations.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard